NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 10 மணி நேரத்திற்கு முன்இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Insecticides India released the transcript of its Q2 FY27 earnings call held on November 05, 2026. The company reported 8% revenue growth in Q2 despite adverse weather and Super El Nino disruptions, while H1 revenue saw a 2% degrowth. Management outlined strong traction in its 'Kaeros' brand platform, projecting brand revenue of ~INR 125 crore this year (out of ~INR 200 crore standalone) and targeting a doubling next year. Capex projects at Dahej and Sotanala are nearing completion, after which the major capex cycle will conclude to focus on DCS plants and CDMO opportunities.
உச்சம் நம்பிக்கை
என்ன மாறியதுFiling of the full transcript of the Q2 & H1 FY27 earnings conference call held on November 05, 2026.
ஏன் இது முக்கியம்Provides management commentary on monsoon disruptions, premium product expansion (aiming for 70% share), and completion timeline for the ongoing capex cycle.
📅 குறுகிய காலம்Neutral as this is a transcript filing of previously reported Q2 financial performance without fresh price-sensitive earnings surprises.
📈 நீண்ட காலம்Transition toward higher-margin premium products (70% target) and the conclusion of the Dahej/Sotanala capex cycle should aid cash flow and margin expansion.
⚠ அபாய எச்சரிக்கைகள்
Elevated inventory and debtor levels impacting working capital
Weather disruptions and El Nino impact on crop yields and pesticide application windows
👀 கவனிக்க வேண்டியவை
Monitor Dahej capitalization completion in December and working capital normalization (inventories and debtors) in subsequent quarters.
Q2 FY27 Net Profit Drops 5% to Rs 56.17 Cr Despite 8% Revenue Growth to Rs 686.31 Cr
Insecticides (India) Limited reported an 8% YoY rise in consolidated Q2 FY27 revenue from operations to Rs 686.31 cr, supported by premiumisation. However, Profit After Tax declined 5% YoY to Rs 56.17 cr, weighed down by higher interest costs. For H1 FY27, revenue dipped 2% YoY to Rs 1,297.84 cr while PAT fell 15% YoY to Rs 100.04 cr amid weather-related demand disruptions. Working capital expanded, with cash cycle days increasing to 158 days in H1 FY27 from 151 days in H1 FY26.
உச்சம் நம்பிக்கை
என்ன மாறியதுInsecticides (India) reported its Q2 and H1 FY27 results, showing subdued half-yearly sales and margin compression due to weather disruptions and higher interest expenses.
ஏன் இது முக்கியம்Higher interest costs and a stretched working capital cycle (158 days) are eroding bottom-line performance despite top-line resilience in Q2.
Q2 FY27 Revenue: Rs 686.31 கோடிQ2 FY27 PAT: Rs 56.17 கோடிQ2 FY27 EBITDA Margin: 13.5%H1 FY27 Working Capital Days: 158 நாட்கள்H1 FY27 PAT YoY Growth: -15%
📅 குறுகிய காலம்Earnings pressure and elevated working capital may keep sentiment muted over the coming weeks.
📈 நீண்ட காலம்Growth hinges on the premiumisation strategy, capacity expansion at Sotanala and Dahej, and scaling higher-margin patented products.
⚠ அபாய எச்சரிக்கைகள்
Weather and monsoon variability causing erratic pesticide application windows
Rising interest costs hurting net margins
Elongating working capital cycle (158 days in H1 FY27)
👀 கவனிக்க வேண்டியவை
Track working capital moderation and debt levels in subsequent quarters, alongside Rabi season demand recovery and contribution from new products Granuvia and Spinoace.
Q2 FY27 Net Profit Down 8.6% YoY to ₹50.58 Cr; Declares ₹5/Share Interim Dividend
Insecticides (India) reported standalone Q2 FY27 revenue from operations of ₹680.18 Cr, up 6.1% YoY compared to ₹641.25 Cr in Q2 FY26. Standalone net profit for the quarter fell 8.6% YoY to ₹50.58 Cr from ₹55.31 Cr, while growing 20.9% QoQ from ₹41.83 Cr. For H1 FY27, revenue declined 2.7% YoY to ₹1,296.66 Cr and net profit contracted 17.9% YoY to ₹92.41 Cr. The Board declared an interim dividend of ₹5 per equity share (50% of face value) with a record date of November 12, 2026.
உச்சம் நம்பிக்கை
என்ன மாறியதுInsecticides (India) approved its Q2/H1 FY27 financial results, declared a ₹5 per share interim dividend, and appointed key management personnel.
ஏன் இது முக்கியம்While Q2 revenue expanded modestly (+6.1% YoY), profitability contracted due to higher input and operational costs, dragging H1 PAT down by 17.9% YoY.
Q2 FY27 Standalone Revenue: ₹68,017.57 lacsQ2 FY27 Standalone PAT: ₹5,057.59 lacsQ2 FY27 EPS: ₹17.38Interim Dividend: ₹5 per shareDividend yield on current price (₹546.5): ~0.9%
📅 குறுகிய காலம்Muted to slightly cautious reaction as profitability decline (-8.6% YoY) offsets modest top-line growth, with the ₹5 dividend providing minor support.
📈 நீண்ட காலம்Long-term performance hinges on portfolio premiumization towards high-margin Maharatna products and managing Kharif/Rabi monsoon-related volatility.
⚠ அபாய எச்சரிக்கைகள்
Input cost inflation squeezing gross margins
H1 net profit contraction of 17.9% YoY
👀 கவனிக்க வேண்டியவை
Track margin recovery in H2 FY27 amid ongoing raw material cost pressures and monitor the interim dividend record date of November 12, 2026.
Insecticides India Q2 PAT Falls 5% to ₹56.17 Cr; H1 Net Cash Flow Negative at -₹73.39 Cr
Insecticides (India) Limited released its Q2 & H1 FY27 earnings presentation, showing consolidated Q2 PAT declined 5% YoY to ₹56.17 crore compared to ₹59.11 crore in Q2 FY26. For H1 FY27, consolidated PAT decreased 15% YoY to ₹100.04 crore on an EBITDA of ₹160.05 crore (down 8% YoY). Cash flow from operations turned negative at -₹73.39 crore for H1 FY27, primarily driven by a ₹210.91 crore working capital absorption. The company continued its shift toward premium formulations, with premium products making up 58% of B2C sales in FY26.
உச்சம் நம்பிக்கை
என்ன மாறியதுInsecticides India published its Q2 and H1 FY27 operational and financial performance review.
ஏன் இது முக்கியம்Demonstrates margin compression and working capital elongation (negative operating cash flow), requiring an increase in short-term debt to fund inventory and receivables.
📅 குறுகிய காலம்Subdued earnings performance and negative operating cash flows in H1 could keep sentiment muted in the near term.
📈 நீண்ட காலம்Long-term trajectory depends on scaling premium Maharatna products, R&D commercialization via patents, and managing working capital cycles efficiently.
⚠ அபாய எச்சரிக்கைகள்
Negative operating cash flow (-₹73.39 Cr in H1 FY27) driven by rising receivables and inventories
Substantial increase in short-term borrowings from ₹125.50 Cr (Mar-26) to ₹220.96 Cr (Sep-26)
👀 கவனிக்க வேண்டியவை
Track working capital unwinding and cash collection in H2 FY27 to see if operating cash flows normalize and short-term debt is repaid.
Insecticides India Q1 FY27 Call: Revenue Down 12% to ₹612 Cr; ₹200 Cr Sotanala Capex on Track
Insecticides (India) reported a 12% YoY decline in Q1 FY27 revenue to ₹612 Cr from ₹691 Cr due to delayed and uneven monsoons impacting Kharif sowing and pesticide demand. EBITDA contracted by approximately 20% with EBITDA margins declining to 11.1%, while PAT margin fell to 7.2%. Gross margin improved to 31.6% (from 29.0%) led by higher contribution from premium Maharatna products, which comprised 64% of B2C sales. Management affirmed that the ₹200 Cr Sotanala capex is progressing with ₹70 Cr spent to date, after which annual capex will normalize to ₹30-40 Cr.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company released its Q1 FY27 earnings call transcript detailing monsoon-led demand deferrals, premiumization traction, and execution timelines for its Sotanala plant.
ஏன் இது முக்கியம்Demonstrates product mix resilience with expanding gross margins despite revenue de-growth, while the ₹200 Cr capex (~16.5% of net worth) nears completion to support technicals manufacturing.
Q1 FY27 Revenue: INR 612 CrRevenue YoY Growth: -12%Gross Margin: 31.6%Sotanala Total Capex: INR 200 CrSotanala Capex vs Net Worth: ~16.5%Post-Expansion Maintenance Capex: INR 30-40 Cr
📅 குறுகிய காலம்Volume recovery in Q2 depends on the distribution and intensity of August rains across core rice, cotton, and soybean growing states.
📈 நீண்ட காலம்Margin profile and return ratios are poised to benefit as the investment cycle closes, maintenance capex drops to ₹30-40 Cr, and Sotanala capacity ramps up.
⚠ அபாய எச்சரிக்கைகள்
Delayed monsoon and weather anomalies affecting seasonal pesticide application
Crude and petroleum-linked raw material price volatility squeezing formulations margins
Elevated inventory levels at the end of June due to deferred season start
👀 கவனிக்க வேண்டியவை
Monitor Kharif application demand recovery in Q2/Q3 FY27 and track commercialization timelines for the Sotanala formulation unit expected by April-May next year.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Q1 FY27 PAT drops 24% to ₹44 Cr; Revenue down 12% on rainfall deficit
Insecticides (India) Limited reported a weak start to FY27, with Q1 revenue declining 12% YoY to ₹612 crore, primarily due to a rainfall deficit across India impacting agrochemical demand. While gross margins expanded by 240 bps to 31.6% through disciplined pricing, EBITDA fell 20% to ₹68 crore and PAT dropped 24% to ₹44 crore. The company is countering this by doubling its 'IIL Crop Solutions' (ICS) plots and launching new products like GRANUVIA in collaboration with Corteva Agriscience. Despite the quarterly dip, management remains focused on its 'premiumization' strategy targeting higher-margin Maharatna products.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company experienced a double-digit decline in both top-line and bottom-line performance for Q1 FY27, reversing the growth trend seen in previous quarters due to adverse weather conditions.
ஏன் இது முக்கியம்The results highlight the company's high sensitivity to monsoon patterns, which can disrupt the application window for pesticides. However, the margin expansion suggests that the shift toward premium products is providing some cushion against volume declines.
📅 குறுகிய காலம்The stock may face downward pressure in the short term as the market reacts to the 24% decline in PAT and the impact of the rainfall deficit on Kharif season sales.
📈 நீண்ட காலம்The long-term outlook depends on the successful execution of the 'premiumization' strategy and the contribution of patented molecules, which management expects to yield margins over 50%.
👀 கவனிக்க வேண்டியவை
Investors should monitor the recovery of demand in Q2 FY27, which is historically a high-revenue quarter (Sep 2025 revenue was ₹637.7 cr). Watch for the sales ramp-up of newly launched patented molecules like GRANUVIA and Spinoace to see if they can offset volume losses in legacy products.
Q1 Net Profit drops 27% YoY to ₹41.83 Cr on 11% Revenue decline
Insecticides (India) Limited reported a weak start to FY27, with standalone revenue for Q1 ending June 30, 2026, declining 10.8% YoY to ₹616.48 Cr. Net profit fell more sharply by 27% YoY to ₹41.83 Cr, down from ₹57.30 Cr in the same period last year. The margin contraction was exacerbated by a significant jump in 'Purchase of Stock-in-Trade,' which rose to ₹76.71 Cr from ₹29.49 Cr YoY. While sequential performance improved (Revenue up 44% QoQ), the YoY decline suggests a challenging environment compared to the previous year's high base.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company reported its Q1 FY27 financial results, marking a double-digit decline in both revenue and profitability compared to the previous year's first quarter.
ஏன் இது முக்கியம்Q1 is a critical period for agrochemical companies due to the Kharif season; a 27% drop in profit indicates potential pricing pressure or volume loss in a key period, despite the company's long-term focus on high-margin patented molecules.
📅 குறுகிய காலம்The stock is likely to face downward pressure in the near term as the market reacts to the YoY earnings miss and margin compression.
📈 நீண்ட காலம்The structural story depends on the successful shift toward 'Maharatna' products (35-40% margins) and R&D for patented molecules, though current results show cyclical headwinds.
⚠ அபாய எச்சரிக்கைகள்
Significant increase in stock-in-trade costs
Year-on-year revenue contraction
Seasonality and monsoon dependency
👀 கவனிக்க வேண்டியவை
Monitor the progress of the monsoon and its impact on Q2 application windows, as the company is sensitive to rainfall patterns. Investors should track if the 'premiumization' strategy and 'Maharatna' products can offset the current weakness in legacy product volumes.
Insecticides (India) FY26 Revenue Up 7% to ₹2,140 Cr; Premium Products Grow 24% in Q4
Insecticides (India) Limited reported a 7% year-on-year revenue growth to ₹2,140 crore for FY26, supported by a strong 19% growth in the final quarter. While EBITDA rose 3% to ₹227 crore, PAT saw a marginal decline to ₹139 crore primarily due to a ₹9 crore increase in deferred tax provisions. The company's focus on premiumization is evident, with EBITDA margins expanding from 6.8% to 10.6% over a three-year period, and ROCE improving to 16.1%. Management also announced the induction of next-generation leadership and the proposal of ESOPs to retain talent.
முக்கிய அம்சங்கள்
Revenue from operations increased 7% YoY to ₹2,140 crore in FY26, with Q4 revenue growing by 19%.EBITDA margins improved to 10.6% in FY26, up from 6.8% three years ago, while ROCE reached 16.1%.Premium products saw a robust 24% growth in Q4; patented products contributed ₹322 crore to the annual top line.The company plans a maintenance capex of ₹25-₹30 crore for FY27 following the completion of major projects.New strategic initiatives include the launch of the 'Kaeros' platform and expanded partnerships with Corteva and Nissan.
👀 கவனிக்க வேண்டியவை
Investors should focus on the company's successful transition toward high-margin premium and patented products, which now represent a significant portion of revenue. The improving return ratios (ROCE and ROE) and disciplined capex plan suggest a strengthening balance sheet and better cash flow potential for FY27.
Insecticides (India) Q4 Revenue Up 19% to ‹426 Cr; FY26 PAT Dips 2% to ‹139 Cr
Insecticides (India) Limited reported a strong 19% YoY revenue growth in Q4FY26, reaching ‹426 crore, driven by a 24% increase in premium product sales. For the full year FY26, revenue grew 7% to ‹2,140 crore, though Profit After Tax (PAT) marginally declined by 2% to ‹139 crore. EBITDA margins saw a slight contraction from 11.1% to 10.6% due to a challenging operating environment marked by erratic rainfall. The company continues to focus on innovation-led growth, launching five new products in FY26 and expanding collaborations with global partners like Corteva.
முக்கிய அம்சங்கள்
Q4 revenue increased by 19% YoY to ‹426 crore, supported by strong B2C and B2B traction.Full-year FY26 PAT stood at ‹139 crore, a 2% decrease compared to ‹142 crore in FY25.Premium products delivered robust growth of 24% during the final quarter of the fiscal year.EBITDA for FY26 was ‹227 crore with a margin of 10.6%, down from 11.1% in the previous year.Introduced 5 new products in FY26, bringing the total to over 25 launches in the last three years.
👀 கவனிக்க வேண்டியவை
While top-line growth is encouraging, the slight dip in PAT and margin contraction suggests cost pressures; watch for margin recovery in upcoming quarters. The shift towards a premium product mix and global collaborations remains a key long-term positive for the stock.
Insecticides (India) Limited reported a total turnover of ₹2,140 Cr for FY26, showcasing a successful transition toward a premium product mix. The company achieved significant margin expansion over a three-year period, with Gross Profit margins rising 840 bps to 31.5% and EBITDA margins reaching 10.6%. Capital efficiency also improved markedly, with ROCE climbing to 16.1% from 10.4% in FY23. The growth is underpinned by strategic collaborations with global players like Corteva and Nissan, and a B2C segment where premium products now contribute 58% of revenue.
முக்கிய அம்சங்கள்
Total turnover for FY26 reached ₹2,140 Cr with 58% of B2C revenue coming from premium products.EBITDA margins expanded by 380 bps to 10.6% and Gross Profit margins reached 31.5% in FY26.Return on Capital Employed (ROCE) improved from 10.4% in FY23 to 16.1% in FY26.Extensive distribution network includes 8,500+ distributors and 70,000+ retailers reaching 7.5 million farmers.Strong R&D focus with 27 patents and a pipeline of new launches scheduled for FY27.
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's ability to sustain margin expansion through its premiumization strategy and international collaborations. The structural improvement in return ratios (ROE/ROCE) makes it a compelling long-term play in the agrochemical sector.
Insecticides (India) FY26 Revenue Jumps 57% to ₹3,144 Cr; Announces New ESPS and Board Changes
Insecticides (India) Limited reported a robust 57% year-on-year growth in standalone revenue for FY26, reaching ₹3,144.17 crore. However, Profit After Tax (PAT) saw a marginal decline to ₹135.14 crore from ₹139.77 crore in FY25, impacted by a significant rise in finance costs and material expenses. The company also announced a new Employee Stock Purchase Scheme (ESPS) for 2,00,000 shares and a key management transition with Mr. Sanskar Aggarwal being appointed as a Whole Time Director.
முக்கிய அம்சங்கள்
FY26 Standalone Revenue from operations increased to ₹3,14,417.11 lacs from ₹2,00,226.58 lacs in FY25.Net Profit for the full year FY26 stood at ₹13,513.74 lacs compared to ₹13,976.56 lacs in the previous year.Finance costs surged by 145% to ₹1,651.20 lacs in FY26 from ₹672.32 lacs in FY25.Board approved IIL ESPS Scheme 2026 involving up to 2,00,000 equity shares with a 1-year lock-in period.Management change: Mr. Sanskar Aggarwal appointed as Whole Time Director for 5 years following the resignation of Mrs. Nikunj Aggarwal.
👀 கவனிக்க வேண்டியவை
Investors should focus on the company's margin compression as the massive 57% revenue growth failed to translate into bottom-line growth. Monitor the impact of rising finance costs and the execution of the new management team in the North region.
Insecticides (India) FY26 Revenue Up 7% to ₹2,144 Cr; Net Profit Dips Slightly to ₹135 Cr
Insecticides (India) Limited reported a 7.1% year-on-year growth in revenue from operations, reaching ₹2,144.17 crore for FY26. However, net profit saw a marginal decline of 3.3%, coming in at ₹135.08 crore compared to ₹139.77 crore in the previous fiscal year, primarily due to a significant spike in finance costs. The board has approved a new Employee Stock Purchase Scheme (ESPS 2026) for 2,00,000 shares and announced key leadership transitions, including the appointment of Mr. Sanskar Aggarwal as a Whole Time Director.
முக்கிய அம்சங்கள்
Total Income for FY26 stood at ₹2,156.28 crore, up from ₹2,009.49 crore in FY25.Net Profit for the year decreased to ₹135.08 crore with an EPS of ₹46.68 (vs ₹47.61 in FY25).Finance costs surged significantly to ₹16.51 crore in FY26 from ₹6.72 crore in the previous year.Board approved ESPS 2026 involving up to 2,00,000 equity shares with a 1-year lock-in period.M/s. T Jain & Associates appointed as Internal Auditors for a five-year term until 2031.
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's ability to manage rising finance costs which impacted the bottom line despite healthy revenue growth. The management transition and new ESPS suggest a focus on long-term leadership stability and employee retention.
Insecticides (India) FY26 PAT Dips 3.3% to ₹135 Cr; Board Approves New ESPS Scheme
Insecticides (India) Limited reported a 7.3% year-on-year growth in total income for FY26, reaching ₹2,156.28 crore. However, net profit for the full year saw a slight decline of 3.3%, settling at ₹135.08 crore, primarily due to a significant spike in finance costs which more than doubled to ₹16.51 crore. The fourth quarter (Q4FY26) showed stronger revenue momentum with a 19.5% YoY increase, though profitability remained relatively flat. Additionally, the board has approved a new Employee Stock Purchase Scheme (ESPS) for 2,00,000 shares and announced key management changes including the appointment of Sanskar Aggarwal as Whole Time Director.
முக்கிய அம்சங்கள்
Total Income for FY26 rose to ₹2,15,628 lacs from ₹2,00,949 lacs in FY25, a growth of 7.3%.Net Profit (PAT) for FY26 decreased by 3.3% YoY to ₹13,507 lacs compared to ₹13,976 lacs.Finance costs surged by 145% YoY to ₹1,651 lacs in FY26 from ₹672 lacs in FY25.Q4 FY26 revenue from operations stood at ₹42,795 lacs, up 19.2% from ₹35,914 lacs in Q4 FY25.Board approved ESPS 2026 for up to 2,00,000 equity shares with a mandatory 1-year lock-in period.
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's ability to manage rising finance costs and interest burdens which are currently eating into profit margins. While revenue growth remains healthy, the slight dip in annual PAT suggests a need for better operational efficiency.
Insecticides (India) Launches GRANUVIATM for Paddy; Offers Up to 60 Days Pest Control
Insecticides (India) Limited has launched GRANUVIATM, a next-generation insecticide developed by Corteva Agriscience and exclusively supplied to IIL. The product targets Brown Plant Hopper (BPH) and Stem Borer in paddy crops, offering a significant 60-day control window for BPH. Since these pests can cause yield losses ranging from 20% to 60%, this high-efficacy product strengthens IIL's position in the massive Indian rice market. The launch is expected to enhance the company's premium product portfolio and improve farmer margins by reducing the frequency of chemical sprays.
முக்கிய அம்சங்கள்
Exclusive supply agreement with global major Corteva Agriscience for the GRANUVIATM brand.Provides long-duration control of Brown Plant Hopper for up to 60 days from application.Targets pests responsible for 10% to 60% yield losses in Indian paddy cultivation.Granular formulation reduces application costs and minimizes the number of required sprays.Product launch strengthens IIL's existing portfolio of 125+ formulation products.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive development that enhances IIL's competitive moat in the paddy segment through exclusive international technology partnerships. Monitor the sales traction during the upcoming Kharif season to gauge the impact on the company's top-line growth.
Insecticides (India) Receives 20-Year Patent for Synergistic Insecticidal Combination
Insecticides (India) Limited has been granted a Patent of Addition by the Government of India for a synergistic insecticidal combination of Diafenthiuron and Acetamiprid. The patent covers the specific wettable powder formulation and the unique process used for its preparation. This patent is valid for a 20-year term effective from the original filing date of July 23, 2013. This development strengthens the company's intellectual property portfolio and provides a competitive edge in the crop protection market.
முக்கிய அம்சங்கள்
Patent granted for a synergistic combination of Diafenthiuron and Acetamiprid in wettable powder form.The patent includes protection for the specific process of preparing the insecticidal combination.The term of the patent is 20 years, calculated from the filing date of July 23, 2013.Grant issued by the Patent Office, Government of India, enhancing the company's R&D-led product pipeline.
👀 கவனிக்க வேண்டியவை
Investors should monitor the commercial contribution of this patented combination to the company's revenue and margins. This grant reinforces the company's focus on high-value, proprietary formulations over generic products.
Insecticides (India) Reports 8% Q3 Revenue Growth; 9M PAT Stands at ₹128 Crores
Insecticides (India) Limited (IIL) delivered a resilient performance in Q3 FY26 with 8% revenue growth, driven by volume expansion and B2B segment strength despite a challenging market. For the 9M FY26 period, revenue reached ₹1,714 crores, up 4% year-on-year, while PAT remained flattish at ₹128 crores due to increased finance and depreciation costs. The company is aggressively pursuing premiumization, with premium products now contributing 59% of the B2C portfolio. Management expects Q4 to remain under margin pressure but maintains a medium-term sustainable growth target of 8-10%.
முக்கிய அம்சங்கள்
9M FY26 revenue increased to ₹1,714 crores from ₹1,641 crores, a growth of 4% YoY.Gross profit for the 9-month period improved by 7% to ₹546 crores, though Q4 margins are expected to face pressure.Premium products now account for 59% of the B2C segment, reflecting a strategic shift away from generics.Launched 5 new products in 9M FY26, including SPARCLE and Altair, with 5 more planned for the upcoming Kharif season.New manufacturing capacities at Dahej and Sotanala are on track to be operational by the end of FY26 and next Kharif respectively.
👀 கவனிக்க வேண்டியவை
Investors should focus on the company's transition toward high-margin premium products and the timely commissioning of the Dahej plant. While near-term margin headwinds persist, the growing share of 'Maharatna' brands and new global collaborations provide a positive medium-term outlook.
Insecticides (India) Q3 Revenue Up 8% to ₹385 Cr; PAT Drops 40% on Margin Pressure
Insecticides (India) Limited reported a mixed Q3 FY26, with revenue growing 8% YoY to ₹385 crore, driven primarily by the B2B segment. However, Profit After Tax (PAT) saw a sharp decline of 40% YoY to ₹10 crore, impacted by higher finance costs, depreciation, and a shift in product mix. For the nine-month period (9M FY26), revenue grew 4% to ₹1,714 crore, while PAT remained flat at ₹128 crore. Management attributed the margin compression to industry-wide headwinds and erratic rainfall affecting the high-margin B2C segment.
முக்கிய அம்சங்கள்
Q3 Revenue from operations increased by 8% YoY to ₹385 crore.Profit After Tax (PAT) for Q3 fell significantly by 40% YoY to ₹10 crore.EBITDA margins contracted to 7.1% in Q3 FY26 from 8.6% in the previous year.Gross profit margins moderated to 32.4% due to a higher B2B sales mix and industry pressures.Launched 5 new products during 9M FY26, including Sparcle and Torry Super, to drive future growth.
👀 கவனிக்க வேண்டியவை
Investors should be cautious due to the significant decline in quarterly profitability and margin contraction. Monitor the company's ability to pass on costs and shift the mix back toward high-margin B2C products in upcoming quarters.
Insecticides (India) Limited has declared an interim dividend of ₹2 per share (20% of face value) for FY 2025-26, with the record date set for February 6, 2026. While consolidated revenue for Q3 FY26 grew by 7.6% YoY to ₹38,491.62 Lacs, the consolidated net profit saw a sharp decline of 39.2% to ₹1,053.82 Lacs. The bottom line was primarily pressured by a significant spike in finance costs, which rose from ₹140.61 Lacs to ₹468.18 Lacs YoY. Additionally, the company confirmed the successful dissolution of its Dubai-based subsidiary, IIL Overseas DMCC.
முக்கிய அம்சங்கள்
Declared an interim dividend of ₹2.00 per equity share (20% of FV ₹10) with a record date of Feb 6, 2026.Consolidated Revenue from Operations increased 7.6% YoY to ₹38,491.62 Lacs in Q3 FY26.Consolidated Net Profit fell 39.2% YoY to ₹1,053.82 Lacs compared to ₹1,733.30 Lacs in the previous year.Finance costs surged by 233% YoY to ₹468.18 Lacs, impacting overall profitability.Basic and Diluted EPS for the quarter dropped to ₹3.60 from ₹5.96 in the year-ago period.
👀 கவனிக்க வேண்டியவை
While the dividend provides a small immediate return, investors should be cautious of the sharp decline in net profit and rising interest expenses. Monitor the company's margin recovery and debt levels in the coming quarters before increasing exposure.
Insecticides (India) Promoters Transfer 67.65% Stake to Family Trusts for Succession Planning
The promoter group of Insecticides (India) Limited has completed an internal reorganization, transferring 1,96,83,052 equity shares, representing 67.65% of the company's share capital, to four family trusts. This transfer was executed as a gift at nil value for the purpose of succession planning and streamlining family assets. The transaction was conducted following a specific exemption granted by SEBI in December 2025, ensuring no open offer was triggered. Since this is an internal reshuffle within the promoter group, the total promoter shareholding remains unchanged.
முக்கிய அம்சங்கள்
Transfer of 1,96,83,052 equity shares (67.65% stake) to family-controlled trusts.Sanskriti Family Trust emerged as the largest holder among the trusts with a 64.66% stake.Transaction executed as an off-market gift with zero monetary consideration.Exemption granted by SEBI under Regulation 11(5) of SAST Regulations to facilitate the transfer.Move is aimed at long-term succession planning and internal reorganization of promoter assets.
👀 கவனிக்க வேண்டியவை
This is a routine internal restructuring for succession planning and does not change the company's fundamentals or management control. Investors should treat this as a neutral event.
Insecticides (India) Board to Meet Jan 30 for Q3 Results and Interim Dividend; Record Date Feb 6
Insecticides (India) Limited has scheduled a board meeting on January 30, 2026, to approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The board will also consider the declaration of an interim dividend for the financial year 2025-26. If a dividend is declared, the company has pre-emptively fixed February 6, 2026, as the record date for determining shareholder eligibility. Additionally, the trading window for insiders has been closed since January 1, 2026, and will remain so until 48 hours after the results are announced.
முக்கிய அம்சங்கள்
Board meeting scheduled for January 30, 2026, to consider Q3 and 9M FY26 financial results.Proposal for an interim dividend for FY 2025-26 to be discussed during the meeting.Record date for the potential interim dividend is fixed as February 6, 2026.Trading window for insiders remains closed from January 1, 2026, until 48 hours post-result declaration.
👀 கவனிக்க வேண்டியவை
Investors should watch for the Q3 earnings performance and the quantum of the interim dividend on January 30. Those looking to qualify for the dividend should ensure they hold the stock before the February 6 record date.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
